Bio Pharma Dive

JULY 28, 2021

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.

Antibody 304

Antibody Drugs Development 304

Bio Pharma Dive

JUNE 18, 2021

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.

Antibody 347

Antibody Drugs 347

Bio Pharma Dive

MAY 24, 2021

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors.

Antibody 320

Antibody Drugs 320

Bio Pharma Dive

NOVEMBER 5, 2020

The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection. Fast antibody testing, however, is spotty.

Antibody 310

Antibody Drugs 310

Bio Pharma Dive

FEBRUARY 10, 2021

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death.

Antibody 310

Antibody Drugs 310

Bio Pharma Dive

OCTOBER 8, 2020

The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use.

Antibody 309

Antibody Drugs 309

Bio Pharma Dive

APRIL 16, 2021

The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug.

Antibody 340

Antibody Drugs 340

Bio Pharma Dive

OCTOBER 7, 2020

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination.

Antibody 338

Antibody Drugs 338

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 296

Antibody Drugs Development 296

Bio Pharma Dive

JANUARY 26, 2021

The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high.

Antibody 338

Antibody Drugs 338

Bio Pharma Dive

SEPTEMBER 16, 2020

The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear.

Antibody 327

Antibody Drugs 327

Bio Pharma Dive

APRIL 14, 2022

Fresh trial results intensify competition with Roche to deliver the first lymphoma drug that marries antibody technology with an immunotherapy pathway.

Drugs 361

Drugs Antibody Trials 361

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Bio Pharma Dive

NOVEMBER 30, 2021

While Regeneron is still testing its treatment against the new variant, the biotech is readying contingency plans, including second-generation versions of its drug.

Antibody 296

Antibody Drugs 296

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs 333

Drugs Antibody Medicine Development 333

Bio Pharma Dive

JUNE 2, 2024

Study results showed the antibody-drug conjugate helped stave off disease progression better than a standard treatment. But eye-related side effects remained common.

Drugs 304

Drugs Antibody 304

Bio Pharma Dive

MAY 25, 2023

Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.

Antibody 323

Antibody Licensing Licensing Drugs 323

Bio Pharma Dive

JANUARY 13, 2021

though many of the issues limiting the drug's use haven't been solved. The deal expands an earlier agreement between Regeneron and the U.S.,

Antibody 312

Antibody Drugs 312

Bio Pharma Dive

FEBRUARY 5, 2024

The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.

Drugs 320

Drugs Antibody 320

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Development Licensing 279

Bio Pharma Dive

DECEMBER 22, 2022

The pharma will pay the Chinese drugmaker $175 million for access to seven preclinical antibody-drug conjugates, deepening ties established this year.

Drugs 309

Drugs Antibody 309

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Bio Pharma Dive

AUGUST 3, 2020

Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.

Nurses 341

Nurses Antibody Drugs 341

Bio Pharma Dive

SEPTEMBER 11, 2023

The HER3-targeting treatment could become the next antibody-drug conjugate to emerge from Daiichi Sankyo’s laboratories, after the AstraZeneca-partnered Enhertu.

FDA Approval 319

FDA Approval Drugs Antibody 319

Bio Pharma Dive

SEPTEMBER 6, 2024

New trial results could offer support for an expansion of Nucala’s label after U.S. regulators rejected GSK’s submission in 2018.

Trials 262

Trials Antibody Regulation Drugs 262

Bio Pharma Dive

SEPTEMBER 21, 2021

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.

FDA Approval 294

FDA Approval Drugs Antibody Medicine 294

Bio Pharma Dive

DECEMBER 23, 2021

The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread.

Antibody 347

Antibody Drugs 347

Bio Pharma Dive

DECEMBER 1, 2020

Working with University of Pennsylvania researcher Jim Wilson, Regeneron aims to develop a nasal spray version of the coronavirus treatment recently cleared by the Food and Drug Administration.

Gene Therapy 284

Gene Therapy Antibody Gene Drugs 284

Bio Pharma Dive

DECEMBER 6, 2022

The second startup to emerge from Star’s “hub-and-spoke” model aims to develop a Hemlibra-like antibody drug for the blood clotting disorder von Willebrand disease.

Drugs 306

Drugs Antibody Development 306

Bio Pharma Dive

MARCH 3, 2021

The NIH stopped enrolling patients hospitalized with coronavirus disease into a study of Vir's antibody drug after data monitors questioned its effectiveness.

Drugs 300

Drugs Antibody 300

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Bio Pharma Dive

JUNE 29, 2023

The yet-to-be-announced deal for the German biotech is the latest move by Lilly to bulk up its oncology business, adding a drug in early development for solid tumors.

Antibody 228

Antibody Drugs Development 228

Bio Pharma Dive

JANUARY 7, 2022

Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.

Drugs 296

Drugs Licensing Licensing Antibody 296

Pharmaceutical Technology

MARCH 4, 2025

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Antibody 182

Antibody Drugs Development 182

Bio Pharma Dive

FEBRUARY 10, 2025

Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requires precision diagnostics.

Antibody 147

Antibody Drugs 147

Bio Pharma Dive

JANUARY 19, 2021

An alliance with Merus, a Dutch biotech, continues Lilly's push to revitalize its oncology research under the leadership of former Loxo Oncology executives.

Antibody 309

Antibody Drugs Research 309